MTOR and cancer: Additionally, our analysis revealed longer PFS in patients with high NK cells, interferons, and RB1 mutations, whereas high cancer-associated fibroblasts levels and mutations in the mTOR signaling pathway and PTPRD were indicators of shorter PFS.